A director at Aehr Test Systems reported a sizable disposition of common stock this month while the company simultaneously announced a record production order and showed mixed quarterly financials.
According to a Form 4 filed with the Securities and Exchange Commission, director Rhea J. Posedel sold 7,500 shares of Aehr Test Systems on April 17, 2026. The reported sale price was $82.00 per share, producing total proceeds of $615,000. At the time of the sale, the companys shares have produced a 937% return over the preceding 12 months and were trading near the directors sale level at $83.86.
Following the transaction, the filing shows that Posedel retains direct ownership of 71,163 shares, a figure that includes unvested restricted stock units. In addition to her direct holdings, Posedel has an indirect interest in 404,479 shares held by a trust.
Corporate developments accompany the insider sale. Aehr Test Systems disclosed a record production order worth $41 million from a hyperscale customer intended for package-level burn-in of custom AI processor ASICs. The company said the order, its largest to date, comprises high-power test and burn-in systems and is slated to begin deliveries in fiscal 2027.
Financial results for Q3 2026 were mixed. Aehr Test Systems posted earnings per share of minus $0.05, which was better than the consensus expectation of minus $0.07. Revenue for the quarter came in at $10.3 million, below the expected $10.8 million. Despite the revenue shortfall, management reported quarterly bookings of $37.2 million and an effective backlog exceeding $50 million, producing a book-to-bill ratio above 3.5 times.
Market watchers have updated their price targets in response to recent company developments. Freedom Broker raised its target to $61 from $38 and maintained a Hold rating, while Lake Street increased its target to $56 from $50 and preserved a Buy rating, citing the companys bookings momentum.
The Form 4 filing documents the insider sale; the companys operational announcements and quarterly metrics provide context for both investor sentiment and analyst reassessments. The combination of a historic production order, substantial bookings, and a strengthened backlog are notable developments occurring alongside the directors sale.